Related by context. All words. (Click for frequent words.) 65 Completes Patient Enrollment 65 Initiates Enrollment 65 liver resection surgeries 64 Initiates Phase II 64 Receives Orphan Drug Designation 64 Completes Enrollment 64 Receives Approvable Letter 64 Pivotal Clinical Trial 63 Enrolls First 63 vapreotide acetate 63 Initiates Clinical Trial 63 Announces FDA Clearance 63 PROMUS R 62 Submits IND 62 Submits Response 62 Investigational Device Exemption IDE 62 PROMUS TM 62 Pivotal Phase III 62 Drug Eluting Coronary Stent 62 Investigational Device Exemption 62 Initiates Clinical 61 BioSante Pharmaceuticals Announces 61 Initiates Phase III 61 Augment ™ 61 Vitrasert R 61 FDA Accepts 61 FDA Approvable Letter 61 FDA Approvals 61 Submits Biologics License Application 61 Announces Tentative Approval 61 Receives FDA Clearance 61 Presents Positive 61 Granted Orphan Drug 61 Pivotal Trial 61 Phase III Clinical Trial 61 Commences Phase 60 Receives CE Marking 60 Successfully Completes Phase 60 Obtains CE Mark 60 Expanded Indication 60 Eluting Coronary Stent System 60 Begins Dosing 60 Pivotal Study 60 Phase 2b Clinical Trial 60 Files Investigational 60 Files IND 60 IND Application 60 LymphoStat B TM 60 IL# PE#QQR 60 TAXUS Element Paclitaxel Eluting 60 Gets FDA Clearance 60 Drug Eluting Stent System 60 Early Relapsing Multiple 60 Fast Track Status 60 Dose Ranging Study 60 Submits NDA 60 FDA Clears 60 granted Ortec 60 ENLIGHT 60 Mylan Receives Approval 60 Embolic Protection 59 Oral Calcitonin 59 Surgical Mesh 59 Therapeutic Competitors Companies 59 lucinactant 59 NexStent 59 Européenne Mark 59 Dementia Related Psychosis 59 Phase IIb Trial 59 Dupuytren Contracture 59 markets HP Acthar 59 Submits Investigational 59 Prospective Randomized 59 Begins Clinical Trial 59 First Patient Enrolled 59 Phase IIIb study 59 Receives Orphan Drug 59 GTC recombinant human 59 VISICOL R 59 Voluntarily Withdraws 59 Receives CE 59 k Premarket Notification 59 DEEP AF 59 TM Drug Eluting 59 Clinical Trial Application 59 NAVISTAR R 58 CIP TRAMADOL ER 58 equine osteoarthritis marketed 58 Presents Preclinical Data 58 Cypher Sirolimus 58 Meets Primary Endpoint 58 Achieves Primary Endpoint 58 Receives Fast Track 58 Initiate Phase 58 Patient Enrollment 58 HYVISC R 58 Phase III Pivotal 58 Receives Milestone Payment 58 Receives Tentative Approval 58 R lenalidomide 58 Premarket Approval PMA 58 ENDEAVOR IV 58 PRN FDA Approves 58 Supplemental Biologics License Application 58 Phase III multicenter 58 Presents Positive Preclinical 58 Embolic Protection Device 58 acetonide FA 58 SPL# Gel vaginal microbicide 58 Clinical Trial Evaluating 58 IND Filing 58 Pafuramidine 58 CryoSeal FS System 58 Intravenous Formulation 58 Premarket Approval Application 58 pregabalin Lyrica 58 Vascular Grafts 58 Demonstrates Positive 58 Receives Complete Response 58 TM Embolic Protection 58 Interactive Orthopedic 58 Phase IIa Clinical Trial 58 Clinical Study Shows 57 Investigational Compound 57 HepaGam B 57 FOLOTYN ® 57 Reports Preclinical Data 57 signal detection CTSD 57 initiated Phase Ib 57 Bone Graft 57 Milestone Payment From 57 V Everolimus Eluting Coronary 57 Vaccine Adjuvant 57 Valtropin 57 RX ACCULINK 57 Risperidone Oral Solution 57 endoluminal stent graft 57 Study Evaluating 57 BioGlue R 57 Endologix Powerlink System 57 Transcept Pharmaceuticals 57 BRILINTA 57 Licenses Novel 57 IONSYS TM 57 PROVENGE ® 57 NDA Submission 57 Initiates Phase 57 Phase IIb Clinical Trial 57 miconazole Lauriad R 57 Liberte TM 57 Angiox ® 57 number NCT# ClinicalTrials.gov 57 Initiate Clinical Trial 57 IV acetaminophen 57 FDA Clearance 57 REPRONEX R menotropins 57 Initiates Phase 2b 57 FACTIVE R gemifloxacin 57 Nasdaq SLXP 57 Taglich Brothers Initiates Coverage 57 Launches Generic Version 57 HepaGam B TM 57 Carotid Stent 57 NYSE MRX 57 Phase IIIb clinical 57 Files Shelf Registration Statement 57 novel oral anticoagulant 57 Taro Receives 57 Web Site http:/www.cryolife.com 57 received CE Conformite 57 NASDAQ BDSI 57 COLAZAL ® 57 RANK Ligand inhibitor 57 Tissue Repair 57 Combination REOLYSIN R 57 II Clinical Trial 57 Acute Decompensated Heart Failure 57 Nasdaq SPPI 57 Patient Enrolment 57 Announce License Agreement 56 Initiates Dosing 56 Powerlink ® 56 Ozurdex 56 Severe Sepsis 56 Phase IIb III 56 k Clearance 56 Sign Licensing Agreement 56 please visit www.abmc.com 56 ibuprofen Injection 56 Spectranetics laser 56 Indevus Pharma 56 Daxor 56 Morphine Sulfate 56 Amends Agreement 56 Submits Application 56 Biomarker Study 56 TAXUS Element Stent System 56 CONBRIZA 56 MelaFind R 56 Commence Phase 56 Investigational Oral 56 Vascular Closure Device 56 Completes Patient Enrolment 56 Rotary VAD 56 iloprost Inhalation Solution 56 NUEDEXTA ™ 56 MedPulser 56 Multaq dronedarone 56 Endeavor Drug Eluting 56 Nasdaq PGNX today 56 SYCREST 56 Bertek Pharmaceuticals 56 Isolator Synergy TM 56 PREVU * POC 56 REPEL CV 56 Approvable 56 faropenem medoxomil 56 Romiplostim 56 Adhesion Barrier 56 Testosterone MDTS ® 56 Augment TM 56 Phase 2b Trial 56 Trobalt 56 submitted supplemental Biologics 56 Retacrit 56 Cordis Cypher 56 Alair Bronchial Thermoplasty System 56 Presents Preclinical 56 Civacir 56 Psoriasis Drug 56 Alimta pemetrexed 56 AVERROES 56 PDUFA Date 56 Humanitarian Device Exemption 56 First Patient Treated 56 Begins Shipment 56 Clinical Trial Results 56 Receives Positive Opinion 56 treat atrial flutter 56 Marketing Approval PMA 56 Medtronic CoreValve ® 56 Ixempra 56 TIGRIS R 56 Application MAA 56 Cintredekin besudotox 56 Metformin HCl 56 Market Approval PMA 56 intravenous acetaminophen 56 VIVITROL ® 56 Methylnaltrexone 56 Oracea TM 56 multicenter Phase 56 delivery polymer matrix 56 AFRS TM 56 Immunotherapeutic 55 subcutaneous formulation 55 BUPHENYL R 55 Premarket Approval 55 Obtains FDA 55 Receives NASDAQ 55 Pivotal Phase 55 Company Nasdaq PRGO 55 Demonstrates Significant 55 mechanical thrombectomy 55 automated radiopharmaceutical distribution 55 pharmacokinetic PK study 55 PROGENSA R 55 Prospective Multicenter 55 pharmacogenomic translational research 55 Nasdaq AVNC 55 Hematological Malignancies 55 FDA approvable letter 55 Embolic Protection System 55 Approvable letter 55 sitaxsentan sodium 55 ARIXTRA R 55 Neovasc Reducer 55 Fast Track designations 55 Dacogen injection 55 reslizumab 55 Clinical Study 55 Receive Milestone Payment 55 Sanvar R 55 endoluminal stent graft ELG 55 dose escalation clinical 55 Sumatriptan Succinate 55 methylnaltrexone bromide 55 By JAMAAL ABDUL 55 index assay IVDMIA 55 Demonstrates Sustained 55 CIP Fenofibrate 55 ferumoxytol Injection 55 Nipent R 55 requiring Asthmatx 55 Rhucin ® recombinant 55 immune globulin intravenous 55 Biologic License Application 55 Efficacy Results 55 Regeneron Pharma 55 BioDelivery 55 coronary stent merged 55 etanercept Enbrel 55 Frova ® 55 Adjunctive Therapy 55 ORENCIA ® 55 Release Capsules 55 highly purified pasteurized 55 Orphan Status 55 TRISENOX ® 55 Glycopyrrolate 55 Patients Treated With 55 Nasdaq RPRX 55 Contrast Enhanced 55 HydroFix 55 testosterone gel LibiGel 55 recombinant thrombin 55 Exherin 55 Refractory Angina 55 Auxilium Pharma 55 Medidur TM FA 55 ANDA Filing 55 Demineralized Bone Matrix 55 Circulatory Support 55 topically applied SEPA 55 GRAS Status 55 SpideRX 55 Afinitor everolimus 55 NeutroSpec TM 55 Commences Phase III 55 ARCOXIA 55 Generic Version 55 aripiprazole Abilify 55 Clinical Trial 55 Absorbable 55 Gamunex C 55 TSX SHQ 55 Marketing Authorisation Application 55 TRANSDUR ™ 55 License Application sBLA 55 Grants Orphan Drug 55 Receives Favorable 55 autologous cellular immunotherapy 55 include Alferon N 55 Abbott Laboratories Terumo 55 Oracea R 55 serotonin norepinephrine reuptake inhibitor 55 ImmuKnow R 55 Melody Transcatheter Pulmonary Valve 55 Optical Biopsy System 55 nasal calcitonin product 55 Personalized Immunotherapy 55 Soliris eculizumab 55 multicenter Phase II 54 oseltamivir Tamiflu ® 54 Combidex 54 TO AVOID PREGNANCY WHILE 54 Novel Oral 54 pulls Darvon painkiller 54 Tissue Matrix 54 Fujisawa Healthcare Inc. 54 Non Invasive Treatment 54 REVLIMID lenalidomide 54 Patent Covering 54 Xenazine ® 54 Receives Subpoena 54 Anidulafungin 54 OTCQX RHHBY 54 FDA Approves 54 Thrombectomy System 54 Inc. Nasdaq VNDA 54 Combination Treatment 54 GENTAMICIN SURGICAL IMPLANT 54 ENESTnd 54 drug eluting coronary stent 54 Keppra ® levetiracetam 54 Alair System 54 Zenvia Phase III 54 Nabi HB Intravenous 54 Phase III Trial 54 SANVAR 54 visit www.noven.com 54 diazepam rectal gel 54 s Zyflo 54 rhBMP 2 54 PATHFINDER R 54 Genotyping Test 54 Biologic License Application BLA 54 Aloxi Injection 54 Kynapid 54 ALVESCO ® 54 Full Prescribing Information 54 CTLM ® 54 LeMaitre Vascular Inc. 54 Barr ANDA 54 RECOTHROM R 54 JOULFERON 54 Submits Supplemental 54 Collaborators Present 54 Daiichi Sankyo Eli Lilly 54 Eculizumab 54 Seasonal Influenza Vaccine 54 #k Clearance 54 mesylate tablets approved 54 pralatrexate injection folate analogue 54 Long Term Efficacy 54 TSXV BIO 54 NASDAQ SOMX specialty 54 Prolongs Survival 54 XIENCE TM 54 phase IIb clinical 54 DAPT Study 54 CancerVax Corporation 54 Mycophenolate Mofetil 54 Confirms Efficacy 54 oral ridaforolimus 54 Custom NX 54 NASDAQ IMDC 54 Trial Evaluating 54 phase IIa clinical 54 ELIQUIS 54 Randomized Phase 54 CERVARIX R 54 Cobalt Pharmaceuticals 54 Initiated Phase 54 superparamagnetic iron oxide nanoparticles 54 Investigational Treatment 54 Augment Bone Graft 54 BOSTON SCIENTIFIC 54 Acute Ischemic Stroke 54 FDA Approval 54 Liprotamase 54 Esbriet ® 54 Immunomedics Announces 54 Single Dose 54 FDA Complete Response 54 Silodosin 54 Earns Milestone Payment 54 OmniWave 54 Teva Provides Update 54 Diabetic Foot Ulcer 54 IDEV Technologies 54 Vascular Disrupting Agent 54 ATryn ® GTC recombinant 54 Mg Uk 54 Generic Versions 54 Solstice Neurosciences 54 Drug Submission 54 Nasdaq ENCY 54 Phase Ib clinical 54 Fondaparinux 54 Saforis 54 Application BLA 54 RIGScan ™ 54 Initiates Voluntary Recall 54 ThermoDox R 54 Inc. NASDAQ HITK 54 ID NCT# 54 Adventrx Pharmaceuticals 54 NexStent Carotid Stent 54 DNAwithPap TM Test 54 Humira adalimumab 54 Tezampanel 54 Phase Ib clinical trials 54 Phase 2a Clinical Trial 54 Regenerative Cells 54 Paragraph IV Notice 54 Corindus 54 Milestone Payment 54 CE Marked 53 Study Demonstrates 53 Ultrasonic Wound 53 Orapred ODT 53 TOPAMAX R 53 Schizophrenia Treatment 53 Aneurysm Repair 53 Successfully Treats 53 Sunesis Pharma 53 AMEX ONI 53 Anticancer Drug 53 Systemic Delivery 53 Sonolith i move 53 Fungal Infections 53 Generx ® 53 Attrius ™ PET 53 Oral Fingolimod 53 Japanese Encephalitis Vaccine 53 Testosterone Gel 53 Reveals Positive 53 Dose Verification System 53 Prostate Cancer Vaccine 53 Not Approvable 53 Skin Cholesterol Test 53 Ercole Biotech 53 visit www.regenbio.com 53 Generic Version Of 53 CRMD# 53 Wellstat 53 Phase #b/#a clinical 53 rHuPH# recombinant human 53 OLpur TM H2H 53 Develop Novel 53 Sestamibi 53 Inhaled Insulin 53 Heart Failure Treatment 53 Oxiplex 53 Phase Ib study 53 eSVS MESH 53 Zenpep 53 Selenia Dimensions System 53 Positive Opinion 53 Artificial Disc 53 Raptiva R 53 Zegerid OTC 53 development DSC# novel 53 NerPharMa 53 Migenix 53 Valera Pharmaceuticals 53 StaphVAX R 53 Decompensated Heart Failure 53 Phase 2a Trial 53 Feraheme ® 53 Eluting Stent 53 Loceryl ® 53 Inc. NASDAQ OSTE 53 eSensor ® 53 enoxaparin sodium injection 53 SUPPRELIN R LA 53 application sNDA 53 Randomized Clinical Trial 53 Bazedoxifene 53 ® darbepoetin alfa 53 onabotulinumtoxinA 53 severe gastroparesis 53 Metastatic Melanoma 53 Vimpat ® lacosamide 53 PresbyLens ® 53 Enzyme Replacement Therapy 53 Receives Clearance From 53 Acute Attacks 53 Controlled Study 53 Alinia 53 Telavancin 53 Devices Advisory Panel 53 Taxus Element 53 Clinical Trial Data 53 Orphan Drug designation 53 Robotic Catheter System 53 XIENCE V Stent System 53 Phase Ib II 53 albiglutide 53 Teflaro 53 MKC# MKC# PP 53 STELARA TM 53 Polymer Microspheres 53 Preclinical Data 53 Recommends Approval 53 Fresenius Biotech 53 Preclinical Study 53 balsalazide tablet 53 Tibotec Therapeutics division 53 AneuRx 53 Advanced Melanoma 53 rasagiline tablets 53 Potent Antiviral Activity 53 Lung Cancer Drug 53 DRUG ADMINISTRATION 53 CONTAK RENEWAL 53 EVLT R procedure 53 ExAblate R 53 APEX PD 53 dependent kinase inhibitor 53 Entereg TM 53 Announces Poster Presentations 53 Announces Favorable 53 OrCel ® 53 Cancidas 53 TearLab TM 53 BrainGate TM 53 SUMAVEL 53 cardiac septal repair 53 Accelerated Approval 53 NeutroSpec 53 PMA Supplement 53 Aldara ® 53 Clinical Trial Enrollment 53 MEK Inhibitor 53 Phase 1b Clinical Trial 53 XGEVA ™ 53 Nasdaq INHX 53 Efficacy Trial 53 Debiopharm SA 53 intranasal formulation 53 AtriCure Isolator 53 Receives Favorable Ruling 53 Receives Marketing Authorization 53 multicenter clinical trials 53 Recombinant Human 53 Begin Clinical Trials 53 Targretin capsules 53 Tesamorelin 53 devicemaker 53 Randomized Phase II 53 Levacor TM 53 buccal tablets 53 supplemental biologics 53 Marketing Authorisation Application MAA 53 CEPHALON 53 Synerx 53 Acute Myocardial Infarction 53 Pluristem Therapeutics 53 sNDAs 53 Complicated Skin 53 Augment ™ Bone Graft 53 Drug Fails 53 Emezine 52 Announces Presentation 52 Nicotine Vaccine 52 Valortim TM 52 Exclusive License 52 Ophthalmic Drugs Advisory 52 LensAR Laser System 52 InSync Sentry 52 Neuromodulation System 52 Receives Approval From 52 Anti CD# Antibody 52 gabapentin enacarbil 52 Initiate Phase III 52 Teikoku Pharma USA 52 NASDAQ CXSP announced 52 Phase III Clinical Trials 52 HCV Protease Inhibitor 52 GTC NASDAQ GTCB 52 CellSearch System 52 T Pred 52 Nivestim 52 oxymorphone ER 52 Respiratory Viral Panel 52 No Objection Letter 52 e mail info@verichipcorp.com 52 Impax ANDA 52 orally disintegrating tablets 52 Resubmission 52 ADVANCE PD 52 Ozarelix 52 RapidBlue TM System 52 Phase Ib IIa 52 Expedited Review 52 Patients Enrolled 52 Noxafil 52 Initiates Clinical Trials 52 Medtronic Infuse 52 Urea Cycle Disorder 52 Plasmin 52 Humanized Anti 52 Receives Tentative FDA 52 Investigational Drug 52 BrachySil ™ 52 Endurant 52 Phase IIIb 52 AFSSAPS 52 Ambulatory EHR ensures 52 Natroba 52 Collaborators Publish 52 Pulmonary Arterial Hypertension 52 Randomized Double Blind 52 OsmoPrep 52 Thrombophilia Risk Test 52 Present Preclinical Data 52 Surgical Adhesive 52 ST Elevation Myocardial 52 TriActiv System 52 JAK2 Inhibitor 52 submitted Biologics License 52 Fully Covered Stent 52 Marketing Authorization Application 52 CIMZIA r 52 Optimark 52 Maleate 52 Intravitreal 52 Phase 2a clinical 52 Hsp# Inhibitor 52 Arno Therapeutics 52 Cardiac Resynchronization Therapy 52 WorldHeart Announces 52 PROMUS Element Stent System 52 SPARLON 52 Nexavar sorafenib tablets 52 Arthritis Drug 52 FDA Orphan Drug 52 Aryplase 52 Avoid jalapenos 52 Kinase Inhibitor 52 EVEREST II 52 PHASE III 52 Fast Track Designation 52 Nuclear Pharm Assist 52 Multiple Ascending Dose 52 Pivotal Phase II 52 Diabetic Ulcers 52 banned Darvon Darvocet 52 rilonacept 52 GORE TAG 52 Curon Medical 52 AMEX BVX 52 Placebo Controlled Trial 52 Genetic Analyzer 52 pDNA vaccine 52 Oncobionic 52 received CE Marking 52 levetiracetam Keppra 52 LUMINATE 52 HeartMate ® 52 microwave ablation system 52 pseudobulbar affect PBA 52 Novel Antibiotic 52 VALSTAR 52 Phase Ib Clinical Trial 52 Phase 1a clinical 52 Obtains Exclusive Rights 52 Receives Notice Related 52 Melphalan 52 Abdominal Stent Graft 52 TG MV 52 Complete Response 52 Inc. OTCBB CEXI 52 Orphan Drug designations 52 Cardio3KG 52 Confirmatory Phase 52 Paxil paroxetine 52 UCB Keppra 52 Ohr Pharmaceutical Inc. 52 Transdermal Patch 52 Amex PTN 52 Genpharm 52 Contrast Agent 52 Regains Full 52 REG2 52 Acute Coronary Syndromes 52 Enrolling Patients 52 Endovascular Valve Edge 52 Package Insert 52 Issued Patent 52 Oracea ® 52 Demonstrates Potential 52 Glatiramer Acetate 52 Viatronix 52 HE4 test 52 Inc. OTCBB VODG 52 Lilly Cymbalta 52 EVIZON TM 52 Embolization 52 HuMax TAC 52 Transmyocardial Revascularization TMR 52 NasdaqCM RPRX today 52 Phase 2b clinical 52 Horizant ™ 52 C1 Inhibitor 52 Fluconazole 52 Cerezyme Fabrazyme Myozyme Aldurazyme 52 Reveals Receipt 52 clinical trial 52 Patent Issued 52 Verigene ® 52 OTC Zegerid 52 Iressa gefitinib 52 Administration TGA 52 Protease Inhibitor 52 Systemic Sclerosis 52 Soliris TM eculizumab 52 Australian Therapeutic Goods 52 Terminates Agreement 52 Nasdaq ICOS 52 Staar Surgical 52 JAK Inhibitor 52 Newly Diagnosed Multiple Myeloma 52 SpineAlign 52 Pandemic Influenza Vaccine 52 Conditional Approval 52 FDA Okays 52 Fixation Device 52 Pharmacokinetics PK 52 injectable formulations 52 OLEPTRO 52 Clinical Evaluation 52 Corgenix Medical Corporation 52 Cloretazine ® 52 Cardiac Rhythm 51 Alza Corporation 51 pediatric rehydration 51 FullTerm 51 ADVERSE EVENTS 51 NitroMist 51 molecular diagnostic assay 51 Recurrent Glioblastoma 51 Cellegesic 51 Kiacta 51 Veregen TM 51 DuraHeart TM 51 Kristalose ® lactulose 51 Simulect 51 PATHFINDER ® 51 BrachySil 51 Proven Effective 51 Oral Insulin Capsule 51 Drug Administration KFDA 51 Stent Restenosis 51 Bryan Cervical Disc 51 Molecular Diagnostic Test 51 Polyzene R F 51 Endotoxin Activity Assay 51 InfuSystem Holdings Inc. 51 XIAFLEX ™ 51 Renal Artery 51 Somatuline R Autogel R 51 protein hydrogel 51 ReliOn Ultima 51 Eluting 51 HP Acthar R 51 HDAC Inhibitor 51 Obtains Approval 51 Medi Span ® 51 Current Controlled Trials 51 carotid stents 51 ENTEREG ® 51 Terbinafine 51 AstraZeneca PLC AZN AZN.LN 51 Product Monograph 51 MelaFind ® 51 Percutaneous Tibial Nerve Stimulation 51 Focalin XR R 51 visit smith.com 51 Ltd Therapeutic Competitors 51 Surfaxin lucinactant 51 CONX 51 Therapeutic Efficacy 51 Phase 2b Study 51 Tuberculosis Vaccine 51 Sanctura XR 51 BioElectronics Corporation Announces 51 Daclizumab 51 NexMed Receives 51 Sapacitabine 51 Anti infective 51 vaccine Synflorix 51 Phase IIA 51 cerebral oximeter 51 Small Molecule 51 Menaflex implant 51 Esbriet pirfenidone 51 Restructures Operations 51 RX Acculink 51 Oncolytic 51 Vertex hepatitis C 51 Clinical Trials Update 51 Cervical Disc 51 ZEGERID Chewable Tablets 51 MAA submission 51 Surfactant Technology 51 hydralazine hydrochloride 51 Serious Side Effects 51 DYSPORT TM 51 successfully commercialize Silenor 51 Novolimus 51 rivaroxaban Xarelto 51 hypervascular tumors 51 PROTONIX 51 injectable formulation 51 Tibotec Pharmaceuticals Ltd. 51 Dural Sealant 51 Improves Survival 51 Aztreonam Lysine 51 Rotarix ® 51 carotid stent 51 Toctino ® alitretinoin 51 Study Showed 51 RapidMist 51 Celsion Corporation 51 Ventricular Assist Device 51 Luveniq 51 investigational 51 Metabolic Disease 51 Azathioprine 51 intravenous iclaprim 51 HCl Injection 51 Hematide ™ peginesatide 51 Ranolazine 51 QuadraSphere 51 email info@verichipcorp.com 51 FDA Warns 51 Receives Unsolicited 51 OROS ® 51 Pulminiq 51 Therapeutic Vaccine 51 IIa Clinical Trial 51 Nasdaq DIGE News 51 pipeline ImmunoGen collaborators 51 Tissue Engineered 51 Reports Receipt 51 Bracco Diagnostics Inc. 51 Cordis Endovascular 51 Orphan Drug status 51 please visit www.eisai.com 51 treat infantile spasms 51 Act PDUFA date 51 Gets Subpoena 51 orally disintegrating 51 Milestone Payments 51 Settle Patent Dispute 51 Directorate TPD 51 phase IIa 51 Company NYSE KVa 51 Nasdaq OSCI 51 Unstable Angina 51 Nexavar sorafenib 51 Pooled Analysis 51 Insmed Incorporated NASDAQ INSM 51 Inhalation Solution 51 Significantly Improves 51 enoxaparin sodium 51 INVOS R 51 authority Gurian Sherman 51 Nasdaq NOVN 51 www.vioquestpharm.com 51 Double Blind Placebo 51 LEUKINE 51 PMA submission 51 Receives SFDA Approval 51 Initiate Phase II 51 Phase IIB 51 OMP designation 51 Focetria 51 XLTEK 51 Exaeris Inc. 51 Complete Response letter 51 Swissmedic 51 Cx# [002] 51 Rilonacept 51 estradiol gel 51 catheter securement 51 Romidepsin 51 Polymerase Inhibitor 51 solifenacin succinate 51 Solstice Neurosciences Inc. 51 Commercialize Novel 51 cetrorelix pamoate 51 Blood Thinner 51 atypical Hemolytic Uremic Syndrome 51 supplemental Biologics License Application 51 Neupro R 51 vivo glucose 51 Sprint Fidelis Leads 51 Pivotal Trials 51 midstage studies 51 metformin accumulation 51 multicenter randomized Phase III 51 PERLANE 51 Medtronic CoreValve System 51 CardioFit 51 Sprycel dasatinib 51 Marketing Authorization Applications 51 Feasibility Trial 51 Partnering Agreements 51 Premarket Notification 51 VBLOC TM 51 NICE Recommends 51 Automated Breast Ultrasound 51 Drug Eluting 51 Survivin antagonist 51 Computed Tomographic 51 PRISTIQ 51 Ortho Dermatologics 51 Cellegesic TM nitroglycerin ointment 51 Medisorb R 51 dba Vitro Biopharma 51 Drug Coated Stent 51 Junovan TM 51 Amex PME 51 TearLab Corporation 51 Effectively Treats 51 Response Biomedical Corporation 51 Evicel 51 Hepatitis B Vaccine 51 Treatment Naïve 51 Cinryze ™ 51 Heart Transplant Recipients 51 Stavzor 51 Marketing Authorisation 51 diarrhea predominant irritable 51 Dabigatran etexilate 51 BioSTAR R 51 Xolegel 51 Diabetic Neuropathy 51 Removab 51 Phase IIa trial 51 Microplasmin 51 orphan designation 51 treat menorrhagia 51 Revo MRI 51 Approvable Letter